Jeffrey A. Robl

Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

Masato Furuhashi, Gürol Tuncman, Cem Z. Görgün et al. · Nature · 2007 · 724 citations · Full text

Fatty-acid-binding Protein Ap2, Metabolic Syndrome, Biochemistry +7

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 617 citations · Full text

An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits

John R. Wetterau, Richard E. Gregg, Thomas Harrity et al. · Science · 1998 · 268 citations

Hyperlipidemia, Whhl Rabbits, Metabolic Syndrome +17

Dual Metalloprotease Inhibitors:  Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase

Jeffrey A. Robl, Chong‐Qing Sun, Jay Stevenson et al. · Journal of Medicinal Chemistry · 1997 · 198 citations · Full text

Hypertension, Chemical Biology, Medicinal Chemistry +17

Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP)

Richard Sulsky, David R. Magnin, Yanting Huang et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 150 citations · Full text

Lipid Synthesis, Biochemistry, Natural Sciences +6